Log in

NASDAQ:SURFSurface Oncology Stock Price, Forecast & News

$6.30
-0.23 (-3.52 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.20
Now: $6.30
$6.65
50-Day Range
$2.57
MA: $4.75
$6.53
52-Week Range
$1.15
Now: $6.30
$7.66
Volume450,058 shs
Average Volume744,805 shs
Market Capitalization$178.42 million
P/E RatioN/A
Dividend YieldN/A
Beta2.63
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
Surface Oncology logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.32 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SURF
CUSIPN/A
CIKN/A
Phone617-714-4096

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.36 million
Book Value$2.03 per share

Profitability

Net Income$-54,790,000.00

Miscellaneous

Employees76
Market Cap$178.42 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive SURF News and Ratings via Email

Sign-up to receive the latest news and ratings for SURF and its competitors with MarketBeat's FREE daily newsletter.

Surface Oncology (NASDAQ:SURF) Frequently Asked Questions

How has Surface Oncology's stock been impacted by COVID-19 (Coronavirus)?

Surface Oncology's stock was trading at $2.37 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SURF stock has increased by 165.8% and is now trading at $6.30. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Surface Oncology?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Surface Oncology.

When is Surface Oncology's next earnings date?

Surface Oncology is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Surface Oncology.

How were Surface Oncology's earnings last quarter?

Surface Oncology Inc (NASDAQ:SURF) announced its quarterly earnings data on Tuesday, May, 12th. The company reported $0.74 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.43 by $0.31. The firm had revenue of $38.59 million for the quarter, compared to analysts' expectations of $38.59 million. Surface Oncology had a negative return on equity of 38.44% and a negative net margin of 70.90%. View Surface Oncology's earnings history.

What price target have analysts set for SURF?

2 brokers have issued 1-year price objectives for Surface Oncology's shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate Surface Oncology's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 42.9% from the stock's current price. View analysts' price targets for Surface Oncology.

Has Surface Oncology been receiving favorable news coverage?

Headlines about SURF stock have been trending negative on Sunday, InfoTrie reports. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Surface Oncology earned a news impact score of -2.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the near term. View the latest news about Surface Oncology.

Are investors shorting Surface Oncology?

Surface Oncology saw a increase in short interest in June. As of June 15th, there was short interest totaling 364,700 shares, an increase of 267.6% from the May 31st total of 99,200 shares. Based on an average daily volume of 1,900,000 shares, the short-interest ratio is presently 0.2 days. Approximately 3.2% of the company's stock are short sold. View Surface Oncology's Current Options Chain.

Who are some of Surface Oncology's key competitors?

What other stocks do shareholders of Surface Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surface Oncology investors own include Allena Pharmaceuticals (ALNA), Verizon Communications (VZ), Enterprise Products Partners (EPD), Alteryx (AYX), Netflix (NFLX), Vertex Pharmaceuticals (VRTX), Xilinx (XLNX), Carnival (CCL), Enphase Energy (ENPH) and Pfizer (PFE).

Who are Surface Oncology's key executives?

Surface Oncology's management team includes the following people:
  • Mr. Daniel S. Lynch, Exec. Chairman (Age 61)
  • Mr. J. Jeffrey Goater, CEO, Pres & Director (Age 44)
  • Dr. Vito J. Palombella, Chief Scientific Officer (Age 56)
  • Dr. Robert W. Ross, Chief Medical Officer (Age 45)
  • Ms. Jessica Fees, Sr. VP of Fin. & Bus. Operations and Treasurer (Age 47)

When did Surface Oncology IPO?

(SURF) raised $84 million in an IPO on Thursday, April 19th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI acted as the underwriters for the IPO.

What is Surface Oncology's stock symbol?

Surface Oncology trades on the NASDAQ under the ticker symbol "SURF."

How do I buy shares of Surface Oncology?

Shares of SURF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Surface Oncology's stock price today?

One share of SURF stock can currently be purchased for approximately $6.30.

How big of a company is Surface Oncology?

Surface Oncology has a market capitalization of $178.42 million and generates $15.36 million in revenue each year. The company earns $-54,790,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis. Surface Oncology employs 76 workers across the globe.

What is Surface Oncology's official website?

The official website for Surface Oncology is www.surfaceoncology.com.

How can I contact Surface Oncology?

Surface Oncology's mailing address is 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-714-4096 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.